At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 15 enrolled
Drug / intervention
Sofosbuvir/Velpatasvir/Voxilaprevir [SOF/VEL/VOX] +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
deLIVER: Direct Acting Antiviral Effects on the Liver
In Brief
A Phase 4 clinical trial evaluating Sofosbuvir/Velpatasvir/Voxilaprevir [SOF/VEL/VOX] and Sofosbuvir/Velpatasvir (SOF/VEL) for HCV Coinfection and 2 related conditions. Completed, enrolled 15 participants across 1 site.
Detailed Summary
Open-label, partially-randomized plasma and liver sampling study to assess hepatitis C virus (HCV) kinetics during treatment with two (Sofosbuvir/Velpatasvir) or three (Sofosbuvir/Velpatasvir/Voxilaprevir) direct acting antivirals (DAAs)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHCV Coinfection, Liver Disease, HIV
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedOct 2016
Enrollment StartJan 2017
Primary CompletionSep 2019
Study CompletionSep 2020
TodayJul 2026
First PostedOct 19, 2016
Enrollment StartJan 1, 2017
Primary CompletionSep 30, 2019
Study CompletionSep 30, 2020
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 9.7 years ago
Interventions
Sofosbuvir/Velpatasvir/Voxilaprevir [SOF/VEL/VOX]drug
antiviral therapy for HCV
Sofosbuvir/Velpatasvir (SOF/VEL)drug
antiviral therapy for HCV